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Introduction
Current cytotoxic chemo-radiotherapy selectively targets proliferating cancer cells.
Quiescent or dormant cancer cells in contrast are often drug resistant and are a major impediment to cancer therapy (1, 2) . Cancer stem-like (CS-like) cells or tumor-initiating cells (3) (4) (5) maintain a quiescent or dormant state, which appears to contribute to their resistance to conventional therapies (6) (7) (8) . Recently, several therapeutic strategies have targeted inhibition of the CS-like cell quiescent state. For example, treatment with arsenic trioxide enhanced the sensitivity of Leukemia stem cells (LSCs) to cytosine arabinoside through inhibition of LCS quiescence (9) . Acute myeloid leukemia stem cells can be induced to enter the cell cycle and apoptosis by treatment with granulocyte colony-stimulating factor (10) . However, it is still unclear whether CS-like cells in solid tumors can also be eliminated by inducing them to cycle.
Viruses can infect target cells, multiply, cause cell death and release viral particles.
These features enable the use of viruses as anticancer agents that induce specific tumor lysis (11, 12) . Adenoviral E1A, in particular, has been shown to exert tumor suppressive functions, including enhancement of chemoradiotherapy-induced apoptosis via inhibition of the cellular DNA repair machinery (13) , and inhibition of cell proliferation via suppression of epidermal growth factor receptor (EGFR) (14) and HER2 (15) . It has been recently reported that an oncolytic adenovirus efficiently eradicates CS-like cells as well as non-CS-like cells in brain tumors, breast cancer, and esophageal cancer (16) (17) (18) .
In the present study, we isolated CD133 + subpopulations from radioresistant cells in human gastric cancer cell lines and characterized them as CS-like cells. By using multicolor cell cycle imaging that color-codes the quiescent CS-like cells and proliferating non-CS-like cells, we demonstrated the treatment dynamics that a genetically engineered telomerase-specific oncolytic adenovirus, OBP-301 (19, 20) eradicates dormant CD133 + CS-like cells via cell-cycle mobilization both in tumor spheres and in subcutaneous tumors.
Materials and Methods

Cell lines and radiation treatment.
The human gastric cancer cell lines MKN45 and MKN7 were maintained according to the vendor's specifications (21) . Radioresistant MKN45 and MKN7 cells were established by administration of radiation treatments using an X-ray generator (MBR-1505R; Hitachi Medical Co.)
Recombinant adenoviruses.
The recombinant tumor-specific, replication-selective adenovirus vector OBP-301 (Telomelysin), in which the promoter element of the human telomerase reverse transcriptase (hTERT) gene drives the expression of E1A and E1B genes linked to an internal ribosome entry site, was previously constructed and characterized (19, 22) .
Isolation of CD133 + and CD133 -cells by flow cytometry.
After incubated with an anti-CD133/2(293C)-Allophycocyanin antibody (Miltenyi Biotec), CD133 + cells were sorted by flow cytometry using FACSAria flow cytometer (Becton Dickinson). CD133 + and CD133 − cells were separated by flow cytometry just before each experiment to ensure that the purity of the CD133 + population was greater than 70%, and the purity of CD133 − cells was above 99%.
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Western blot analysis.
The primary antibodies used were: mouse anti-CD133/1(W6B3C) monoclonal antibody (mAb) (Miltenyi Biotec), rabbit anti-E2F1 polyclonal antibody (pAb) (Santa Cruz Biotechnology), mouse anti-Ad5 E1A mAb (BD Pharmingen), mouse anti-c-Myc pAb, rabbit anti-phospho-Akt mAb, rabbit anti-Akt mAb, mouse anti-p27 mAb (all three from Cell Signaling Technology), mouse anti-p53 mAb, mouse anti-p21 mAb (both from CALBIOCHEM Merck4 Biosciences), and mouse anti-β-actin mAb (Sigma-Aldrich).
Immunoreactive bands on the blots were visualized using enhanced chemiluminescence substrates (ECL Plus; GE Healthcare). (4 mg/body weight (kg)) was intraperitoneally injected and ionizing radiation (2 Gy) was performed into tumors after protection of normal tissues. Mice were treated every 3 days for a total of three treatments.
Imaging of MKN45 cells expressing cell cycle-dependent fluorescent proteins.
Time-lapse images of FUCCI expressing CD133 + and CD133 − radioresistant MKN45 cells were acquired using a confocal laser scanning microscope (FV10i; Olympus). Cross-sections of FUCCI-expressing tumors were imaged using confocal laser scanning microscope (FV-1000; Olympus).
Treatment of subcutaneous FUCCI-expressing MKN45 tumors.
To evaluate the in vivo antitumor efficacy of OBP-301, cisplatin, paclitaxel or combination, the FUCCI-expressing MKN45 cells were inoculated at a density of 5 × 10 6 cells/site into the flank of 5-week-old female athymic nude mice (Charles River Laboratories). OBP-301 (1 × 10 8 PFU/tumor) was injected into the tumors. Cisplatin (4 mg/kg) and paclitaxel (5 mg/kg) were injected intraperitoneally. Mice were treated every 3 days for a total of three to five Yano et al., Page 9 treatments.
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Statistical analysis.
Data are shown as means ± SD. For comparison between two groups, significant differences were determined using Student's t-test. For comparison of more than two groups, statistical significance was determined with a one-way analysis of variance (ANOVA) followed by a
Bonferroni multiple group comparison test. P values of < 0.05 were considered significant.
Results
CD133
+ cells in human gastric cancer cells are cancer stem-like.
CS-like cells are more resistant to radiotherapy than non-CS-like cells (24) (25) (26) Fig. S4 and Fig. 1B) . Furthermore, CD133 + cells in radioresistant MKN45 and MKN7 cells were significantly more resistant to 5-fluorouracil, cisplatin, paclitaxel, and radiation than CD133 − cells (Fig. 1C and Supplementary Fig. S1B ).
These data indicate that CD133 + cells are CS-like. S8 ), suggesting that these proteins are involved in the maintenance of quiescent CS-like cells. Fig. 2A and Supplementary Fig. S1B ).
Quiescent
Next To further explore the efficacy of OBP-301 against CD133 + CS-like cell, we assessed the relationship between hTERT activity and viral replication. OBP-301 contains the hTERT promoter, which allows it to tumor-specifically regulate the gene expression of E1A and E1B
for viral replication (19 
OBP-301 mobilizes and lethally traps quiescent CS-like cells into S-phase in monolayer
culture.
To examine whether OBP-301 could change the cell cycle phase of quiescent CD133 (27) and decreased the expression of p53, p21 and p27 proteins that function as cell cycle brakes (27) in quiescent CD133 + cells (Fig. 2D ). In contrast, cisplatin and radiation increased the expression of p53 and p21 proteins ( Formation of tumor spheres under serum-free conditions is frequently used to maintain CS-like cell subpopulations (28) . The addition of serum makes floating undifferentiated tumor spheres migrate from sphere to adherent cells and differentiate into adherent cells (29) . Therefore, we hypothesized that tumor sphere maintained CS-like cell frequency due to be quiescent. CD133 + cells at each cell cycle in three-dimensional culture gathered, formed tumor spheres, and became in G 0 /G 1 phase (Fig. 3A) . Tumor spheres from CD133 + cells contained more quiescent cells than those from CD133 − cells (Fig. 3B) .
Moreover, the established tumor spheres from CD133 + cells in three-dimensional culture without serum remained quiescence (Fig. 3C ). In contrast, the established tumor spheres, after adding serum, exited from quiescent state and began to cycle, divide and increase ( Fig.   3C and Supplementary Movie S2). Flow cytometric analysis demonstrated that CD133 + cells could be maintained in tumor spheres cultured in serum-free medium for 2 weeks, whereas the percentage of CD133 + cells significantly decreased in CD133 + cells cultured in monolayer cultures or in tumor spheres cultured in serum-containing medium (Fig. 3D ).
These data indicate that tumor sphere maintains CSC frequency keeping dormant.
Real-time imaging spatiotemporally shows OBP-301 eliminates dormant tumor spheres mRNA at 2 weeks after the final treatment (Fig. 5B) . In contrast, although cisplatin and radiation also suppressed tumor growth to a similar extent as OBP-301 (Fig. 5A ), cisplatin
Yano et al., Page 15 did not affect, and radiation significantly increased CD133 mRNA expression at 1 week after the final treatment (Fig. 5B) . Immunohistochemistry of CD133-stained tumor sections also showed that OBP-301 reduced the frequency of CD133 + cells, whereas cisplatin and irradiation increased compared with control (Fig. 5B ).
Next we visualized the treatment dynamics in established FUCCI-expressing MKN45
tumor xenografts with or without OBP-301 infection ( Supplementary Fig. S10B ). formation of CD133 + cells (Fig. 6A and Supplementary Fig. 13 ). Tumor spheres treated with chemotherapy and OBP-301 contained an increased percentage of tumor cells at G 2 /M phases compared to OBP-301 alone (Fig. 6B) . The combination of OBP-301 and chemotherapy ( Supplementary Fig. S10C ) significantly suppressed the tumor growth compared to chemotherapy or OBP-301 alone ( Fig. 6C and Supplementary Fig. S14 ). Cross-sections of tumor tissues demonstrated that combination of chemotherapy and OBP-301 induced an increased percentage of tumor cells at G 2 /M phases compared to OBP-301 alone (Fig. 6D) .
These results suggest that OBP-301 sensitizes the quiescent CS-like cells to chemotherapy-mediated G 2 /M arrest by inducing cell cycle progression and S/G 2 /M-phase-trapping.
Discussion
Here we have described that a bioengineered telomerase-specific oncolytic adenovirus, OBP-301, efficiently kills CD133 + CS-like cells that have higher telomerase activity through enhanced E1A-mediated cell-cycle mobilization and S-phase-trapping. By using FUCCI technology in combination with tumor-sphere culture, we visualized the virus penetration, the cell-cycle dynamics, and the subsequent elimination of quiescent CS-like cells in dormant tumor spheres ( Supplementary Fig. S15A ).
CS-like cells have been shown to be highly resistant to chemotherapeutic agents (32, 33) and ionizing radiation (24) (25) (26) Recent studies have showed that p53 and p21 cip1/waf1 maintain the quiescent state in hematopoietic stem cells (34, 35) . Moreover, p27 kip1 has been suggested to be involved in experiments. Data are shown as means ± SD (n = 5). *P < 0.05, **P < 0.01. Immuofluorescent staining was visualized by confocal laser microscopy. Scale bars, 100 μm.
Data are shown as means ± SD (n = 5). *P < 0.01. 
